This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (146)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Venous Thromboembolism  • Cardiovascular System  • Evidence-Based Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Joel G. Ray, MD, FRCP

Arch Intern Med. 1998;158:2101-2106.

Background  Elevated plasma homocysteine (Hcy) levels are implicated in the development of atherosclerotic and venous thromboembolic disease. A meta-analysis of the risk for venous thromboembolism (VTE) in the presence of hyperhomocysteinemia (hyper-Hcy) was performed.

Methods  Studies were identified through MEDLINE (January 1980 to August 1997) using search terms related to both Hcy and VTE. The bibliographies of all review articles and letters were searched for additional relevant articles. English-language studies were selected if they included 10 or more human subjects; a measurement of the plasma, serum, or whole-blood Hcy level; the presence of VTE; and primary data that were not published elsewhere. Seventy-two articles were retrieved, of which 9 met all inclusion criteria. Data were extracted on the study type, subject demographics, methods for matching control subjects with case patients, whether an objective method was used to diagnose VTE, and whether other causes of thrombophilia and elevated Hcy levels were considered. The mean Hcy levels, both in the fasting state and following methionine loading, if done, were recorded, as were the number of patients and control subjects with Hcy levels greater than 2 SDs or greater than the 95th percentile above the mean value of the control group.

Results  Nine case-control studies measured fasting plasma Hcy levels, and 5 also measured Hcy values after methionine loading. All 9 studies showed a similar qualitative trend in fasting levels in the associated risk for hyper-Hcy and VTE. The corresponding pooled odds ratio was 2.95 (95% confidence interval, 2.08-4.17; 2-sided P <.001), with no evidence for heterogeneity across the studies (P=.50). Following methionine loading, the trend was also toward increasing the risk of VTE with hyper-Hcy (odds ratio, 2.15; 95% confidence interval, 1.20-3.85; 2-sided P=.01). Again, no evidence of heterogeneity was found (P=.65). The pooled odds ratio for VTE in the presence of hyper-Hcy rose to 4.37 (95% confidence interval, 1.94-9.84) when studies with patients older than 60 years were excluded. Limitations of the individual studies included a lack of proper matching of patients with control subjects, a limited description of subject recruitment, and a failure to test for other hypercoagulable mechanisms and other causes of elevated Hcy levels, such as renal insufficiency or folate deficiency.

Conclusions  A significant risk for VTE in the presence of hyper-Hcy apparently exists among a spectrum of patients with first or recurrent venous thromboembolic events. This risk appears to be most significant for patients with VTE disease before age 60 years. A well-designed prospective study is needed to confirm these findings.

From the Department of Medicine, Women's College Hospital, University of Toronto, and the Department of Clinical Epidemiology and Biostatistics, McMaster University, Toronto, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Should Plasma Homocysteine Be Used as a Biomarker of Venous Thromboembolism? A Case--Control Study
Ducros et al.
CLIN APPL THROMB HEMOST 2009;15:517-522.
ABSTRACT  

Hyperhomocysteinemia Due to Pernicious Anemia Leading to Pulmonary Thromboembolism in a Heterozygous Mutation Carrier
Kupeli et al.
CLIN APPL THROMB HEMOST 2008;14:365-368.
ABSTRACT  

Thrombophilia States and Markers of Coagulation Activation in the Prediction of Pediatric Venous Thromboembolic Outcomes: A Comparative Analysis with Respect to Adult Evidence
Goldenberg
ASH Education Book 2008;2008:236-244.
ABSTRACT | FULL TEXT  

Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism: A Randomized Trial
Ray et al.
ANN INTERN MED 2007;146:761-767.
ABSTRACT | FULL TEXT  

Livedoid vasculopathy: further evidence for procoagulant pathogenesis.
Hairston et al.
Arch Dermatol 2006;142:1413-1418.
ABSTRACT | FULL TEXT  

Incidence and risk factors for development of venous thromboembolism in Indian patients undergoing major orthopaedic surgery: results of a prospective study
Bagaria et al.
Postgrad. Med. J. 2006;82:136-139.
ABSTRACT | FULL TEXT  

Sulfur Amino Acids in Cushing's Disease: Insight in Homocysteine and Taurine Levels in Patients with Active and Cured Disease
Faggiano et al.
J. Clin. Endocrinol. Metab. 2005;90:6616-6622.
ABSTRACT | FULL TEXT  

Pyrosequencing Analysis of Thrombosis-Associated Risk Markers
Holmberg et al.
Clin. Chem. 2005;51:1549-1552.
FULL TEXT  

Review of Thrombophilic States
Beck and Berman
CLIN PEDIATR 2005;44:193-199.
 

Pathogenesis of Atherosclerosis
Crowther
ASH Education Book 2005;2005:436-441.
ABSTRACT | FULL TEXT  

Hyperhomocysteinemia, Low Folate and Vitamin B12 Concentrations, and Methylene Tetrahydrofolate Reductase Mutation in Cerebral Venous Thrombosis
Cantu et al.
Stroke 2004;35:1790-1794.
ABSTRACT | FULL TEXT  

Role of Folate in Colon Cancer Development and Progression
Kim
J. Nutr. 2003;133:3731S-3739.
ABSTRACT | FULL TEXT  

Hyperhomocysteinemia Is Associated With the Presence of Left Atrial Thrombus in Stroke Patients With Nonvalvular Atrial Fibrillation
Ay et al.
Stroke 2003;34:909-912.
ABSTRACT | FULL TEXT  

Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System
Crowther and Kelton
ANN INTERN MED 2003;138:128-134.
ABSTRACT | FULL TEXT  

Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease
De Bree et al.
Pharmacol. Rev. 2002;54:599-618.
ABSTRACT | FULL TEXT  

Homocysteine and Buerger's disease * Authors' reply
Umasankar and Huwez
Postgrad. Med. J. 2002;78:764-764.
FULL TEXT  

Pulmonary Embolism: What Have We Learned Since Virchow?: Natural History, Pathophysiology, and Diagnosis
Dalen
Chest 2002;122:1440-1456.
FULL TEXT  

Hyperhomocysteinemia and Venous Thrombosis
Lee and Prasad
INT J LOW EXTREM WOUNDS 2002;1:4-12.
ABSTRACT  

Low Plasma Levels of Vitamin B6 Are Independently Associated With a Heightened Risk of Deep-Vein Thrombosis
Cattaneo et al.
Circulation 2001;104:2442-2446.
ABSTRACT | FULL TEXT  

Systematic reviews in health care: Systematic reviews of evaluations of prognostic variables
Altman
BMJ 2001;323:224-228.
FULL TEXT  

Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy
Weger et al.
Br J Ophthalmol 2001;85:803-806.
ABSTRACT | FULL TEXT  

Genetic Susceptibility to Venous Thrombosis
Seligsohn and Lubetsky
NEJM 2001;344:1222-1231.
FULL TEXT  

Homocysteine and cardiovascular disease: cause or effect?
Brattstrom and Wilcken
Am. J. Clin. Nutr. 2000;72:315-323.
ABSTRACT | FULL TEXT  

Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events
Booth et al.
CMAJ 2000;163:21-29.
ABSTRACT | FULL TEXT  

Hyperhomocyst(e)inemia and the Increased Risk of Venous Thromboembolism: More Evidence From a Case-Control Study
Langman et al.
Arch Intern Med 2000;160:961-964.
ABSTRACT | FULL TEXT  

Risk Factors for Thromboembolism
Jay
ANN INTERN MED 1999;131:790-790.
FULL TEXT